

Article

Not peer-reviewed version

Modelling the Effectiveness of Sulphadoxine - Pyrimethamine as an Intermittent Preventative Treatment for Malaria in Pregnant Women in Malawi

Ernest Gundo, Patrick Phepa*, Peter Mwamtobe

Posted Date: 24 June 2025

doi: 10.20944/preprints202506.1916.v1

Keywords: IPTp-SP; malaria; pregnant women; Reproduction number



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Modelling the Effectiveness of Sulphadoxine—Pyrimethamine as an Intermittent Preventative Treatment for Malaria in Pregnant Women in Malawi

Ernest Gundo 1,*, Patrick Phepa 2,† and Peter Mpasho Mwamtobe 1,†

- Department of Applied Studies, Malawi University of Science and Technology, 7 km Off Robert Mugabe Highway Near Ndata Farm, Thyolo, 310100, Southern Region, Malawi
- Department of Mathematical Sciences, Malawi University of Business and Applied Sciences, Along Masauko Chipembere Highway, Blantyre, 312225, Southern Region, Malawi
- * Correspondence: erngundo@gmail.com
- [†] These authors contributed equally to this work.

Abstract

A mathematical model incorporating intermittent preventive treatment of malaria using sulfadoxine-pyrimethamine in pregnant women (IPTp-SP) as an intervention strategy is developed and analyzed. The model incorporates both the human host and mosquito vector populations. The stability properties of the equilibrium points are analytically assessed, and numerical simulations are carried out to support and illustrate the theoretical results. The basic reproduction number, R_0 , is shown to fall below unity under the intervention, suggesting the potential for malaria elimination within the pregnant population. A comparative analysis reveals that the intervention significantly enhances disease suppression, supporting its role as an effective strategy for reducing malaria burden among pregnant women.

Keywords: IPTp-SP; malaria; pregnant women; Reproduction number

1. Introduction

Malaria is a significant public health concern in many regions across the globe, particularly in tropical and sub-tropical regions where Anopheles mosquitoes are prevalent [1]. In 2023, the global estimate of malaria cases reached approximately 263 million, with an incidence rate of 60.4 cases per 1,000 individuals at risk [2]. Infants, children under the age of 5, pregnant women and girls, travellers, and people living with HIV or AIDS are at higher risk of severe infection [1]. The disease is caused by Plasmodium parasites (*P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale and P. knowlesi*) transmitted to humans by female Anopheles mosquitoes [3]. The most deadly parasite among Plasmodium species is *P. falciparum*, which is most prevalent on the African continent [1,4]. Not all female Anopheles mosquitoes have malaria [3], but they become infectious when they bite humans carrying the parasite during a blood meal. They then transmit the parasite to other humans, continuing the malaria transmission cycle. The life cycle of malaria is depicted in Figure 1.

Despite efforts to reduce the incidence of malaria, the disease remains a major public health concern [5]. The interventions used for malaria prevention for all groups include vector control, vaccination, and preventive chemotherapies. For pregnant women, intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) is administered exclusively as a prophylactic measure during pregnancy [2,5]. When prevention fails, infected individuals are prescribed treatment based on the severity of their condition and their general health status to treatments such as artesunate and artemisinin-based combination therapy [2].




Figure 1. Illustration of the malaria life cycle, showing the stages of parasite development within the mosquito vector and human host ([3]).

Protecting pregnant women from malarial infections has been a significant challenge in Malawi [5]. Therefore, investigating the effectiveness of sulphadoxine-pyrimethamine as an intermittent preventative treatment for malaria in pregnant women in Malawi is a plausible approach to addressing this issue. According to [5], while everyone is at risk of contracting malaria, pregnant women face a particularly high risk of its adverse consequences due to reduced immunity [6,7]. Their increased vulnerability is attributed to the immunological and physiological changes that occur during pregnancy, which can increase malaria severity and lead to complications such as maternal anaemia, preterm birth, and low birth weight [1,3,6,7]. Pregnant women are three times more likely to develop severe malaria compared to non-pregnant women in the same geographic area [4,8]. In Malawi, IPTp-SP remains a trusted intervention for preventing malaria during pregnancy.

Some studies have suggested that IPTp-SP doses effectively suppress the adverse effects of malaria during pregnancy, and their effectiveness appears to vary depending on the number of doses taken by pregnant women [9,10]. This remains true even in the presence of widespread resistance of Plasmodium species to sulphadoxine-pyrimethamine (SP) [5,11]. Three or more doses of IPTp-SP are the most effective in averting the adverse effects of malaria in pregnant women [10–12].

Compartmental mathematical models of malaria are widely documented in the literature [13]. The pioneering mathematical models of malaria that describe vector-host dynamics, upon which other models of malaria are based, include the Ross-Macdonald models, and the Anderson and May model [13–16]. [17] and [18] adapted these frameworks to variable population size models while trying to describe the disease dynamics of malaria. However, their models did not incorporate any interventions, but provided a framework for studying control strategies for the containment of malaria. [17] developed an SEIRS model that incorporates reinfection due to the loss of immunity in the recovered population. Through numerical simulations, they confirmed that abrupt reductions in the mosquito population may temporarily decrease malaria prevalence but do not lead to elimination in endemic regions. Using the same SEIRS framework, [18] emphasized that lowering R_0 below 1 may not always guarantee malaria eradication due to possible subcritical bifurcations and concluded that targeted interventions must be carefully structured to achieve effective malaria control. [19] suggested

that combining effective antimalarial drugs with comprehensive control measures is essential for reducing transmission and the pool of infectious individuals. [20] developed a mathematical model that analyzed the dynamics of malaria disease transmission and evaluated control strategies for its management. [21] emphasized the importance of applying mathematical models to improve public health strategies against malaria. [22] considered a combination of intervention strategies such as effective mass drug administration and vector control (LLITNs and IRS) to combat and eventually eliminate the malaria. Although various transmission and control compartmental mathematical models of malaria are widely documented in the literature, our proposed model is seemingly new as it investigates the effectiveness of IPTp-SP as a prophylactic treatment for pregnant women.

The proposed compartmental model is not exhaustive. One limitation is that it does not specify the number of doses pregnant women are receiving. The recommended number of IPTp-SP doses during pregnancy is at least three, with the first dose administered as early as possible at the beginning of the second trimester, but not before week 13 of pregnancy [2].

In the following sections, we formulate and analyze a deterministic model incorporating IPTp-SP as an intervention strategy. Key parameters influencing transmission are identified through sensitivity analysis of the model. Finally, some parameter values are assumed within realistic ranges to support the analytical results, with the caveat that model outcomes are not compared with real data.

2. Methods: Model Formulation and Description

The population of pregnant women is divided based on malaria and dosing status. When malaria invades, it categorizes them into non-intersecting classes: susceptible (S_p) , exposed (E_p) , infected (I_p) , and recovered (R_p) , with X_is representing susceptible pregnant women who receive any number of IPTp-SP doses (one, two, or at least three). Similarly, vectors are classified based on their malaria status. When malaria spreads among vectors, it divides them into non-intersecting classes: susceptible (S_v) , exposed (E_v) , and infected (I_v) . The total population of pregnant women at any time is given by:

$$N_{\nu}(t) = S_{\nu}(t) + X_{i}(t) + E_{\nu}(t) + I_{\nu}(t) + R_{\nu}(t). \tag{1}$$

And the total population of vectors at any given time is given by:

$$N_v(t) = S_v(t) + E_v(t) + I_v(t).$$
 (2)

The recruitment rate of pregnant women through conception is Λ , while ζ represents the recruitment rate of the mosquitoes through birth. The natural death rates of pregnant women and mosquito populations are μ_p and μ_v , respectively, with these rates being proportional to the number of individuals or mosquitoes in each class. The biting rate of mosquitoes is α . The fraction of susceptible pregnant women taking IPTp-SP prophylaxis is denoted as (κ_i) , while the fraction not taking IPTp-SP prophylaxis is given by $(1-\kappa)$. The fraction of pregnant women protected from malaria due to IPTp-SP effectiveness, (ε_i) , transitions directly to the recovered class (R_p) at the treatment success rate (η_i) . Conversely, $(1-\varepsilon)$ represents the fraction of pregnant women who contract malaria at a treatment failure rate $(1-\eta)$. Male (microgametocytes) and female (macrogametocytes) gametocytes are ingested by Anopheles mosquitoes during a blood meal from an infected pregnant woman at the rate:

$$\lambda_v(t) = \frac{\alpha \beta_{pv} I_p(t)}{N_p(t)},$$

where β_{pv} is the success rate of gametocyte transmission from an infected pregnant woman to susceptible mosquitoes. Thereafter, susceptible mosquitoes enter the exposed class $E_v(t)$. During this stage, gametocytes fuse, generating zygotes that later develop into oocytes, which eventually rupture to release sporozoites. At this point, mosquitoes transition into the infected class $I_v(t)$ at the rate v_v . Mosquitoes may die from the disease at the rate δ_v in the infected class. During a subsequent blood

meal, malaria-infected female Anopheles mosquitoes inoculate sporozoites into pregnant women at the rates:

 $\lambda_{pi}(t) = rac{lphaeta_{vpi}I_v(t)}{N_p(t)},$

and

$$\lambda_p(t) = \frac{\alpha \beta_{vp} I_v(t)}{N_p(t)},$$

where β_{vpi} and β_{vp} represent the success rates of sporozoite transmission from infected mosquitoes $I_v(t)$ to susceptible pregnant women taking IPTp-SP prophylaxis (κ_i) and those not taking IPTp-SP prophylaxis $(1-\kappa)$, respectively, during a blood meal. This transitions pregnant women into the latent stage, $E_p(t)$. Upon infection, sporozoites invade liver cells, where they mature and multiply before rupturing and releasing merozoites. These merozoites then infect red blood cells, continuing a cycle of replication. The blood-stage parasites cause the disease's symptoms and clinical manifestations, transitioning pregnant women into the infected class $I_p(t)$ at the rate v_p . Infected pregnant women may die from the disease at the rate δ_p or move to the recovered class, R_p , at the rate γ_p . Once immunity wanes, they return to the susceptible class, S_p , at the rate ω_p . Figure 2 provides a graphical interpretation of the malaria compartmental model




Figure 2. Flowchart for malaria model with IPTp-SP as an intervention. The dash lines show that the infected mosquitoes (I_v) infect the susceptible individuals (S_p) and (X_i) , the infected pregnant women (I_p) infect the susceptible mosquitoes (S_v) .

Based on our model description, assumptions, definitions of the state variables and parameters in Table 1, the proposed $S_p X_i E_p I_p R_p S_p$ malaria model satisfies the following system of non-linear ordinary differential equations:

$$\frac{dS_{p}}{dt} = \Lambda + \omega_{p}R_{p} - \kappa_{i}S_{p} - \Gamma\lambda_{p}S_{p} - \mu_{p}S_{p}$$

$$\frac{dX_{i}}{dt} = \kappa_{i}S_{p} - \varepsilon_{i}\eta_{i}X_{i} - \Omega_{i}\lambda_{pi}X_{i} - \mu_{p}X_{i}$$

$$\frac{dE_{p}}{dt} = \Gamma\lambda_{p}S_{p} + \Omega_{i}\lambda_{pi}X_{i} - \nu_{p}E_{p} - \mu_{p}E_{p}$$

$$\frac{dI_{p}}{dt} = \nu_{p}E_{p} - (\gamma_{p} + \delta_{p} + \mu_{p})I_{p}$$

$$\frac{dR_{p}}{dt} = \gamma_{p}I_{p} + \varepsilon_{i}\eta_{i}X_{i} - \omega_{p}R_{p} - \mu_{p}R_{p}$$

$$\frac{dS_{v}}{dt} = \zeta - \lambda_{v}S_{v} - \mu_{v}S_{v}$$

$$\frac{dE_{v}}{dt} = \lambda_{v}S_{v} - \nu_{v}E_{v} - \mu_{v}E_{v}$$

$$\frac{dI_{v}}{dt} = \nu_{v}E_{v} - (\mu_{v} + \delta_{v})I_{v}$$

$$(3)$$

where:

$$\Gamma = (1 - \kappa_i)$$

and

$$\Omega_i = (1 - \varepsilon_i)(1 - \eta_i)$$

Table 1. The parameters and description for the malaria model.

| Parameter | Description |
|-----------------------|---|
| $\overline{\Lambda}$ | The rate of conception of pregnant women |
| ζ | The rate of recruitment of mosquitoes through natural birth |
| μ_p | Natural death rate of pregnant women per capita |
| μ_v | The natural death rate of mosquitoes per capita |
| ν_p | Transfer rate of pregnant women from the exposed state to the infectious state |
| $\dot{ u_v}$ | The rate of transfer of mosquitoes from the exposed state to the infectious state |
| β_{vp} | The infectivity of mosquitoes |
| β_{pv} | The infectivity of pregnant women |
| α | The man-biting rate of mosquitoes. |
| δ_p | The disease induced death rate per capita for pregnant women |
| $\dot{\delta_v}$ | The disease induced death rate per capita for mosquitoes |
| γ_p | Recovery rate of pregnant women with partial immunity |
| $\dot{\omega_p}$ | The rate of losing immunity and going back to the susceptible |
| η_i | Treatment success rate of doses of IPTp-SP |
| $\dot{\varepsilon}_i$ | Fraction of pregnant women protected from malaria by IPTp-SP |
| κ_i | Fraction of pregnant women taking IPTp-SP |

3. Results

3.1. Invariant Region

Both the model state variables and parameters are assumed non-negative for all time $t \ge 0$. Let $(S_p, X_i, E_p, I_p, R_p, S_v, E_v, I_v) \in \mathbb{R}^8$ be any solution of the system with non-negative initial conditions. Applying Birkhoff and Rota's Theorem [23] on differential inequality, from Equation (1), we have

 $N_p(t) \le \Lambda - \mu_p N_p$ as $t \to \infty$, and thus, $0 \le N_p(t) \le \frac{\Lambda}{\mu_p}$. Hence the feasible solutions on the human population enter the region

$$\Pi_p = \left\{ \left(S_p, X_i, E_p, I_p, R_p \right) \in \mathbb{R}^5_{\geq 0} : N_p(t) \leq \frac{\Lambda}{\mu_p} \right\}. \tag{4}$$

Similarly, it can be shown that the feasible solutions on the mosquito population given by Equation (2) enter the region

$$\Pi_{v} = \left\{ (S_{v}, E_{v}, I_{v}) \in \mathbb{R}^{3}_{\geq 0} : N_{v}(t) \leq \frac{\zeta}{\mu_{v}} \right\}.$$
 (5)

Therefore, from (4) and (5), the possible solutions of model (3) will enter the positively invariant region $\Pi = \Pi_p \times \Pi_v$.

3.2. Positivity of the State Variables

Since is a positively invariant set under the flow induced by model (3), we now show that every solution with initial condition in \mathbb{R}^8 remains in that region for t > 0.

Theorem 1. The solution set $\{S_p, X_i, E_p, I_p, R_p, S_v, E_v, I_v\}(t)$ of the malaria model (3) with the initial condition $\{S_p, X_i, E_p, I_p, R_p, S_v, E_v, I_v\}(0)$ is positive for all t > 0.

Proof. Let $t = \sup\{t > 0 : S_p > 0, X_i > 0, E_p > 0, I_p > 0, R_p > 0, S_v > 0, E_v > 0, I_v > 0\} \in [0, t],$ gives t > 0. The first equation of model (3) gives

$$\begin{split} \frac{dS_p}{dt} &= \Lambda + \omega_p R_p - \kappa_i S_p - \Gamma \lambda_p S_p - \mu_p S_p \\ \frac{dS_p}{dt} &\geq -S_P(t) (\kappa_i + \Gamma \lambda_p + \mu_p) \\ S_p(t) &\geq S_p(0) e^{-\left(\int_0^t \Gamma \lambda_p(s) \, ds + (\kappa_i + \mu_p)t\right)} \geq 0 \end{split}$$

The second equation of the model (3) gives

$$\begin{split} \frac{dX_i}{dt} &= \kappa_i S_p - \varepsilon_i \eta_i X_i - \Omega_i \lambda_{pi} X_i - \mu_p X_i \\ \frac{dX_i}{dt} &\geq -X_i (\varepsilon_i \eta_i + \Omega_i \lambda_{pi} + \mu_p) \\ X_i(t) &\geq X_i(0) e^{-\left(\int_0^t \Omega_i \lambda_{pi}(s) ds + (\varepsilon_i \eta_i + \mu_p)t\right)} \geq 0 \end{split}$$

Hence S_p and X_i is always positive for all t > 0.

The third equation of model model (3) gives

$$\frac{dE_p}{dt} = \Gamma \lambda_p S_p + \Omega_i \lambda_{pi} X_i - \nu_p E_p - \mu_p E_p$$

$$\frac{dE_p}{dt} \ge -E_p (\nu_p + \mu_p)$$

$$E_p(t) \ge E_p(0) e^{-(\nu_p + \mu_p)t} \ge 0$$

Similarly it can be shown that $I_p > 0$, $R_p > 0$, $S_v > 0$, $E_v > 0$, and $I_v > 0$

3.3. Existence and Stability of Steady-State Solutions

The disease-free equilibrium (DFE) of the malaria model (3) denoted by E_0 is given by

$$E_0 = \left(S_p^*, X_i^*, E_p^*, I_p^*, R_p^*, S_v^*, E_v^*, I_v^*\right)$$

At equilibrium we consider the compartments S_p^* , X_i^* and S_v^* of the system (3) which as non-infected compartments. Therefore from equations 1,2, and 6 of the model (3) we have

$$\Lambda - \kappa_i S_p^* - \mu_p S_p = 0 \tag{6}$$

$$\kappa_i S_p^* - \varepsilon_i \eta_i X_i^* - \mu_p X_i^* = 0 \tag{7}$$

$$\zeta - \mu_v S_v^* = 0 \tag{8}$$

From (6) S_p^* is given as:

$$S_p^* = \frac{\Lambda}{(\kappa_i + \mu_p)}$$
$$= c_i \Lambda$$

where

$$c_i = \frac{1}{(\kappa_i + \mu_p)}$$

Substituting S_p^* in (7), we have:

$$X_i^* = \Lambda c_i d_i$$

where

$$d_i = \frac{\kappa_i}{(\varepsilon_i \eta_i + \mu_p)}$$

Therefore:

$$X_i^* = \frac{\kappa_i \Lambda}{(\kappa_i + \mu_\nu)(\varepsilon_i \eta_i + \mu_\nu)} \tag{9}$$

Equation (9) is the general form for finding the disease-free equilibrium points for the IPTp-SP intervention model.

From (8) we can solve for S_v^* to have:

$$S_v^* = \frac{\zeta}{\mu_v}.$$

Consequently, the disease-free equilibrium for the model (3) will be given by:

$$\left(\frac{\Lambda}{(\kappa_i + \mu_p)}, \frac{\kappa_i \Lambda}{(\kappa_i + \mu_p)(\varepsilon_i \eta_i + \mu_p)}, 0, 0, 0, \frac{\zeta}{\mu_v}, 0, 0\right)$$

The effective reproduction number is obtained by using the next generation matrix [24]. Let

$$\mathcal{F} = egin{bmatrix} \Gamma \lambda_p S_p + \Omega_1 \lambda_p X_i \ 0 \ \lambda_v S_v \ 0 \end{bmatrix}$$

and

$$\mathcal{V} = egin{bmatrix} (
u_p + \mu_p)E_p \\ (
\gamma_p + \delta_p + \mu_p)I_p -
u_p E_p \\ (
u_v + \mu_v)E_v \\ (
u_v + \delta_v)I_v -
u_v E_v \end{bmatrix}$$

The effective reproduction number is the spectral radius $\rho(FV^{-1})$ and the resulting expression is given by

$$\alpha \mu_{p} \sqrt{\frac{\zeta \nu_{p} \beta_{pv} \nu_{v} (\Gamma \beta_{vp} (\eta_{i} \varepsilon_{i} + \mu_{p}) + \Omega_{i} \kappa_{i} \beta_{vpi})}{\Lambda \mu_{v} (\mu_{p} + \nu_{p}) (\delta_{v} + \mu_{v}) (\mu_{v} + \nu_{v}) (\kappa_{i} + \mu_{p}) (\gamma_{p} + \delta_{p} + \mu_{p}) (\eta_{i} \varepsilon_{i} + \mu_{p})}}$$
(10)

The effective reproduction number is defined as the number of secondary malaria infections caused by one infectious pregnant woman or mosquito during the infectious period in a completely susceptible population. This number is not only important for describing how quickly the disease could spread, but it can also provide valuable information for controlling and preventing the spread of the disease [22].

3.4. Local Stability of the Disease-Free Equilibrium

Local stability of the DFE is established from the Corollary of the theorem in [25,26].

Corollary 1. Corollary of Gershgorin Circle Theorem: Let A be an $n \times n$ matrix with real entries. If the diagonal elements a_{ii} of A satisfy

$$a_{ii} < -r_i$$

where

$$r_i = \sum_{j=1, j \neq i}^n |a_{ij}|$$

for i = 1...n, then the eigenvalues of A are negative or have negative real parts.

Lemma 1. The DFE for the malaria model (3) is locally asymptotically stable if $R_0 < 1$ and unstable when $R_0 > 1$.

Proof. The Jacobian matrix for (3) at disease-free equilibrium is given as

$$\begin{bmatrix} -d_4 & 0 & 0 & 0 & \omega_p & 0 & 0 & -\frac{\Gamma \alpha \beta_{vp} \mu_p}{d_4} \\ \kappa_i & -h & 0 & 0 & 0 & 0 & 0 & -\frac{\Omega_i \alpha \beta_{vpi} \kappa_i \mu_p}{d_4 h} \\ 0 & 0 & -d_0 & 0 & 0 & 0 & \frac{\Gamma \alpha \beta_{vp} \mu_p}{d_4 h} + \frac{\Omega_i \alpha \beta_{vpi} \kappa_i \mu_p}{d_4 h} \\ 0 & 0 & \nu_p & -d_1 & 0 & 0 & 0 & 0 \\ 0 & \eta_i \varepsilon_i & 0 & \gamma_p & -g & 0 & 0 & 0 \\ 0 & 0 & 0 & -\frac{\alpha \beta_{pv} \mu_p \zeta}{\Lambda \mu_v} & 0 & -\mu_v & 0 & 0 \\ 0 & 0 & 0 & \frac{\alpha \beta_{pv} \mu_p \zeta}{\Lambda \mu_v} & 0 & 0 & -d_2 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & \nu_v & -d_3 \end{bmatrix}$$

where $d_0 = (\nu_p + \mu_p)$, $d_1 = (\delta_p + \gamma_p + \mu_p)$, $d_2 = (\nu_v + \mu_v)$, $d_3 = (\delta_v + \mu_p)$, $d_4 = (\kappa_i + \mu_p)$, $g = (\omega_p + \mu_p)$ and $h = (\varepsilon_i \eta_i + \mu_p)$. According to the corollary, the Jacobian matrix will have negative eigenvalues if the following inequalities are satisfied:

$$d_4 > \frac{\omega_p d_4 + \Gamma \alpha \beta_{vp} \mu_p}{d_4} \tag{11}$$

$$d_{4} > \frac{\omega_{p}d_{4} + \Gamma\alpha\beta_{vp}\mu_{p}}{d_{4}}$$

$$h > \frac{\kappa_{i}d_{4}h + \Omega_{i}\alpha\beta_{vpi}\kappa_{i}\mu_{p}}{d_{4}h}$$

$$(11)$$

$$d_0 > \frac{h\Gamma\alpha\beta_{vp}\mu_p + \Omega_i\alpha\beta_{vpi}\kappa i\mu_p}{d_4h}$$
 (13)

$$d_1 > \nu_v \tag{14}$$

$$g > (\eta_i \varepsilon_i + \gamma_p) \tag{15}$$

$$\mu_v > \frac{\alpha \beta_{pv} \mu_p \zeta}{\Lambda \mu_v} \tag{16}$$

$$d_2 > \frac{\alpha \beta_{pv} \mu_p \zeta}{\Lambda \mu_v} \tag{17}$$

$$d_3 > \nu_v \tag{18}$$

Combining (13),(14),(17) and (18) we have:

$$1 > \frac{\alpha^2 \beta_{pv} \mu_p^2 \zeta \nu_p \nu_v \left(\Gamma \beta_{vp} h + \Omega_i \beta_{vpi} \kappa_i \right)}{\Lambda \mu_v d_0 d_1 d_2 d_3 d_4 h} = R_e^2$$

This shows that the disease disease-free equilibrium is locally asymptotically stable if $R_e < 1$ and unstable if $R_e > 1$. \square

3.5. Existence of Endemic Equilibria

The endemic equilibrium is the equilibrium of the system (3) where the disease persists in the population. The endemic equilibrium point E_1 of the system (3) satisfies $S_p^* > 0$, $X_i^* > 0$, $E_p^* > 0$, $I_p^* > 0, R_p^* > 0, S_v^* > 0, E_v^* > 0, I_v^* > 0.$

If $E_1 = \left(S_p^*, X_i^*, E_p^*, I_p^*, R_p^*, S_v^*, E_v^*, I_v^*\right)$ represents any arbitrary equilibrium of the system (3). Solving the system (3) at equilibrium results into:

$$\begin{split} S_p^* &= \frac{\Lambda + R_p^* \omega_p}{\kappa_i + \Gamma \lambda_p + \mu_p} \\ X_i^* &= \frac{\kappa_i \left(\Lambda + R_p^* \omega_p \right)}{\left(\kappa_i + \Gamma \lambda_p + \mu_p \right) \left(\Omega_i \lambda_{\text{pi}} + \eta_i \epsilon_i + \mu_p \right)} \\ E_p^* &= \frac{\left(\Lambda + R_p^* \omega_p \right) \left(\Gamma \lambda_p \left(\eta_i \epsilon_i + \mu_p \right) + \Omega_i \lambda_{\text{pi}} \left(\kappa_i + \Gamma \lambda_p \right) \right)}{\left(\mu_p + \nu_p \right) \left(\kappa_i + \Gamma \lambda_p + \mu_p \right) \left(\Omega_i \lambda_{\text{pi}} + \eta_i \epsilon_i + \mu_p \right)} \\ I_p^* &= \frac{\nu_p \left(\Lambda + R_p^* \omega_p \right) \left(\Gamma \lambda_p \left(\eta_i \epsilon_i + \mu_p \right) + \Omega_i \lambda_{\text{pi}} \left(\kappa_i + \Gamma \lambda_p \right) \right)}{\left(\mu_p + \nu_p \right) \left(\gamma_p + \delta_p + \mu_p \right) \left(\kappa_i + \Gamma \lambda_p + \mu_p \right) \left(\Omega_i \lambda_{\text{pi}} + \eta_i \epsilon_i + \mu_p \right)} \\ R_p^* &= \frac{\eta_i \epsilon_i \left(\kappa_i \left(\Lambda + i_p \gamma_p \right) + i_p \gamma_p \left(\Gamma \lambda_p + \mu_p \right) \right) + i_p \gamma_p \left(\kappa_i + \Gamma \lambda_p + \mu_p \right) \left(\Omega_i \lambda_{\text{pi}} + \mu_p \right)}{\eta_i \epsilon_i \left(\kappa_i \mu_p + \left(\mu_p + \omega_p \right) \left(\Gamma \lambda_p + \mu_p \right) \right) + \left(\mu_p + \omega_p \right) \left(\kappa_i + \Gamma \lambda_p + \mu_p \right) \left(\Omega_i \lambda_{\text{pi}} + \mu_p \right)} \\ S_v^* &= \frac{\zeta}{\lambda_v + \mu_v} \\ E_v^* &= \frac{\zeta \lambda_v}{\left(\lambda_v + \mu_v \right) \left(\mu_v + \nu_v \right)} \\ I_v &= \frac{\zeta \lambda_v \nu_v}{\left(\delta_v + \mu_v \right) \left(\lambda_v + \mu_v \right) \left(\mu_v + \nu_v \right)} \end{split}$$

where the forces of infection at equilibrium are given by $\lambda_p^* = \frac{\alpha \beta_{vp} I_v^*}{N_p^*}$, $\lambda_{pi}^* = \frac{\alpha \beta_{vpi} I_v^*}{N_p^*}$, $\lambda_v^* = \frac{\alpha \beta_{pv} I_p^*}{N_p^*}$ respectively

3.6. Global Stability of the Endemic Equilibrium

The global stability of the endemic equilibrium for system(3) is analysed.

Theorem 2. If $R_0 > 1$, then the endemic equilibrium point of the model is globally asymptotically stable on \aleph for

$$\nu_p = \frac{(\nu_p + \mu_p)\mu_p}{\alpha \beta_{vp} S_p^*}$$

$$\nu_v = \frac{(\nu_v + \mu_v)\mu_v}{\alpha \beta_{pv} S_v^*}$$

$$\mu_p = \frac{\Lambda}{S_p^*}$$

$$\mu_v = \frac{\zeta}{S_v^*}$$

Proof. We define a Lyapunov function:

$$\begin{split} L(t) &= \frac{1}{\alpha \beta_{vp} S_p^*} \Big(S_p - S_p^* \log S_p \Big) + \frac{1}{\alpha \beta_{pv} S_v^*} (S_v - S_v^* \log S_v) + \frac{1}{\alpha \beta_{vp} S_p^*} E_p + \frac{1}{\mu_p} I_p \\ &+ \frac{1}{\alpha \beta_{pv} S_v^*} E_v + \frac{1}{\mu_v} I_v \end{split}$$

Getting the time derivative we have:

$$\begin{split} L'(t) &= \frac{1}{\alpha \beta_{vp} S_p^*} \left(1 - \frac{S_p^*}{S_p} \right) S_p' + \frac{1}{\alpha \beta_{pv} S_v^*} \left(1 - \frac{S_v^*}{S_v} \right) S_v' + \frac{1}{\alpha \beta_{vp} S_p^*} E_p' + \frac{1}{\mu_p} I_p' \\ &+ \frac{1}{\alpha \beta_{pv} S_v^*} E_v' + \frac{1}{\mu_v} I_v' \\ L'(t) &= \frac{1}{\alpha \beta_{vp} S_p^* S_p} \left(S_p - S_p^* \right) S_p' + \frac{1}{\alpha \beta_{pv} S_v^* S_v} (S_v - S_v^*) S_v' + \frac{1}{\alpha \beta_{vp} S_p^*} E_p' + \frac{1}{\mu_p} I_p' \\ &+ \frac{1}{\alpha \beta_{pv} S_v^*} E_v' + \frac{1}{\mu_v} I_v' \\ L'(t) &= \frac{1}{\alpha \beta_{vp} S_p^* S_p} \left(S_p - S_p^* \right) \left(\Lambda - \frac{\beta_{vp} \alpha I_v}{N_p} S_p - \mu_p S_p \right) \\ &+ \frac{1}{\alpha \beta_{pv} S_v^* S_v} (S_v - S_v^*) \left(\zeta - \frac{\beta_{pv} \alpha I_p}{N_p} S_v - \mu_v S_v \right) \\ &+ \frac{1}{\alpha \beta_{vp} S_p^*} \left(\frac{\beta_{vp} \alpha I_v}{N_p} S_p - \nu_p E_P - \mu_p E_p \right) + \frac{1}{\mu_p} \left(\nu_p E_p - \gamma_p I_p - \delta_p I_p - \mu_p I_p \right) \\ &+ \frac{1}{\alpha \beta_{vv} S_v^*} \left(\frac{\beta_{pv} \alpha I_p}{N_p} S_v - \nu_v E_v - \mu_v E_v \right) + \frac{1}{\mu_v} \left(\nu_v E_v - \delta_v I_v - \mu_v I_v \right) \end{split}$$

After some algebraic manipulations, we have:

$$\begin{split} L'(t) &= -\frac{\Lambda}{\alpha\beta_{vp}S_p^*} \left(\frac{S_p}{S_p^*} + \frac{S_p^*}{S_p} - 2\right) - \frac{\zeta}{\alpha\beta_{pv}S_v^*} \left(\frac{S_v}{S_v^*} + \frac{S_v^*}{S_v} - 2\right) - \left(I_p - \frac{I_p}{N_p}\right) \\ &- \left(I_v - \frac{I_v}{N_v}\right) - \frac{\gamma_p I_p}{\mu_p} - \frac{\delta_p I_p}{\mu_p} - \frac{\delta_v I_v}{\mu_v} \end{split}$$

Clearly, $\left(I_p - \frac{I_p}{N_p}\right) \leq 0$ and $\left(I_v - \frac{I_v}{N_v}\right) \leq 0$ And since the arithmetic mean is greater than or equal to the arithmetic mean we have:

$$\left(\frac{S_p}{S_p^*} + \frac{S_p^*}{S_p}\right) \ge 2$$

and

$$\left(\frac{S_v}{S_v^*} + \frac{S_v^*}{S_v}\right) \ge 2$$

Thus, $L'(t) \leq 0$ for all $(S_p, E_p, I_p, R_p, S_v, E_v, I_v) \in \aleph$. Thus, by the asymptotic stability theorem [27], the positive endemic equilibrium state E_1 is globally asymptotically stable in \aleph . \square

4. Model simulations and Discussions

Numerical simulations of the model system (3) are carried out using python to illustrate some of the analytical results. Parameters values for the model simulation are provided in Table 2, some of these parameters were obtained from literature [5,28–31] while others were assumed (within realistic range) for the purpose of simulations.

Table 2. Parameter values for the malaria model with interventions.

| Parameter | Base Value | Source | Estimated Value |
|------------------|---------------------------|---------|-----------------|
| Λ | 0.0005948 | [28] | 0.188 |
| ζ | 0.071 | [31] | 0.335 |
| δ_v | 0.07 | Assumed | 0.111 |
| α | 0.94 | [30] | 0.977 |
| μ_p | $\frac{1}{49 \times 365}$ | [29] | 0.0984 |
| β_{vp} | 0.00021 | [30] | 0.634 |
| ν_p | $\frac{1}{20}$ | [30] | 0.490 |
| $\dot{eta_{pv}}$ | 0.00021 | [30] | 0.789 |
| δ_p | 0.001 | [30] | 0.223 |
| μ_v | 0.11346 | [30] | 0.257 |
| γ_p | $\frac{1}{30}$ | [30] | 0.0555 |
| ν_v | 0.091 | [30] | 0.223 |
| ω_p | $\frac{1}{20 \times 365}$ | [30] | 0.5000 |
| κ_i | 0.64 | [5] | 0.159 |
| ε_i | 0.25 | Assumed | 0.133 |
| η_1 | 0.25 | Assumed | 0.633 |

The dynamics of the population of pregnant women without treatment are depicted in Figure 3, while those with treatment are shown in Figure 4. The dynamics of the mosquito population are presented in Figure 5.

The impact of administering IPTp-SP dosage within a population of pregnant women is investigated under the assumption that infection occurs exclusively via bites from infectious mosquitoes. The initial condition introduces 100,000 individuals in the latent compartment. Parameter values are drawn from Table 2. Figures 3 and 5 illustrate the dynamics of the pregnant women and mosquito populations, respectively, in the absence of IPTp-SP treatment ($\kappa_i=0$). The corresponding basic reproduction number is estimated at 0.91, indicating that malaria transmission would subside over time even without intervention. For comparison, Figure 4 presents the system dynamics under the implementation of IPTp-SP. A comparative analysis reveals that the intervention significantly enhances disease suppression, supporting its role as an effective strategy for reducing malaria burden among pregnant women.




Figure 3. Pregnant women dynamics showing infection and recovery patterns when IPtp-SP is not in use.




Figure 4. Dynamics of the malaria model with IPTp-SP in use, illustrating its impact on infection rates, transmission reduction, and recovery among pregnant women over time.




Figure 5. Vector dynamics in the basic malaria model, showing transmission patterns.

Introducing a treated proportion of pregnant women, defined by $\kappa_i \in (0,1)$, clearly changes the system dynamics. Notably, there is a substantial increase in transitions to the recovered class among pregnant women, surpassing all other demographic compartments. This effect is likely driven by the reduced incidence of malaria infections under the IPTp-SP intervention, facilitating a more direct pathway to recovery. Moreover, the susceptible population declines to zero in the presence of treatment—contrasting with the no-intervention scenario, where susceptibility remained persistently high.

A mesh plot was employed to generate a three-dimensional representation of the influence of two critical parameters: the proportion of pregnant women receiving IPTp-SP treatment (κ_i) and the treatment success rate (η_i). As shown in Figure 6, the color gradient highlights a marked decline in the basic reproduction number, R_0 , as both κ_i and η_i approach 1. This trend emphasizes the combined effect of high treatment coverage and efficacy, with R_0 values falling below unity when both parameters attain near-optimal levels—indicating the potential for disease elimination under effective intervention strategies.




Figure 6. Mesh plot illustrating the relationship between the fraction of pregnant women receiving IPTp-SP, treatment success rate, and the basic reproduction number R_0 , showing their combined impact on malaria transmission dynamics.

5. Discussion and Conclusions

A compartmental model describing malaria transmission dynamics among pregnant women was developed, integrating both the human host and mosquito vector populations. The stability properties of the equilibrium points were analytically assessed, and numerical simulations were carried out to support and illustrate the theoretical results. Control of infection was examined through the implementation of an IPTp-SP intervention strategy. Analytical investigation demonstrated global stability of the disease-free equilibrium, and the basic reproduction number, R_0 , was shown to fall below unity under the intervention, suggesting the potential for malaria elimination within the pregnant population.

While the model provides valuable insights, it remains a simplification of real-world dynamics and offers several avenues for refinement. For example, the current framework treats the intervention as one, yet stratification into discrete treatment levels—such as single-dose, double-dose, and three or more doses—could provide a more accurate understanding. Ultimately, an integrated model encompassing all treatment levels may offer a more robust depiction of the intervention. Furthermore, the assumption of constant treatment efficacy could be relaxed by incorporating the pharmacokinetics and pharmacodynamics (PK/PD) of IPTp-SP to reflect varying drug concentrations and biological response over time. These improvements could be explored through targeted numerical simulations to evaluate the impact of differential dosing and treatment dynamics on malaria control outcomes.

References

- 1. WHO. Malaria, 2024.
- 2. WHO. WHO guidelines for malaria; World Health Organization: Geneva, 2024; pp. 33 146. https://doi.org/10.2471/b09146.
- 3. CDC. About Malaria, 2024.
- 4. Schantz-Dunn, J.; Nour, N. Malaria and Pregnancy: A Global Health Perspective. *REVIEWS IN OBSTETRICS & GYNECOLOGY* **2009**, *2*, 186–192. https://doi.org/10.3909/riog0091].
- 5. WHO. World malaria report 2024, 2024.
- 6. Guilbert, L.J.; Abbasi, M.; Mosmann, T.R., The immunology of pregnancy: Maternal defenses against infectious diseases; Malaria in Pregnancy Deadly Parasite, Susceptible Host, Taylor & Francis: London, 2001; pp. 56–69. https://doi.org/10.3109/9780203302255-11.
- 7. Doritchamou, J.Y.A.; Aitken, E.H.; Luty, A.J.F. Editorial: Immunity to Parasitic Infections in Pregnancy. *Frontiers in Immunology* **2021**, 12. https://doi.org/10.3389/fimmu.2021.813446.
- 8. Bauserman, M.; Conroy, A.L.; North, K.; Patterson, J.; Bose, C.; Meshnick, S. An overview of malaria in pregnancy. *Seminars in Perinatology* **2019**, *43*, 282–290. https://doi.org/10.1053/j.semperi.2019.03.018.
- 9. Apinjoh, T.O.; Ntui, V.N.; Chi, H.F.; Moyeh, M.N.; Toussi, C.T.; Mayaba, J.M.; Tangi, L.N.; Kwi, P.N.; Anchang-Kimbi, J.K.; Dionne-Odom, J.; et al. Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi longitudinal study. *PLoS ONE* **2022**, *17*, e0275370–e0275370. https://doi.org/10.1371/journal.pone.0275370.
- Agyeman, Y.N.; Newton, S.K.; Annor, R.B.; Owusu-Dabo, E. The Effectiveness of the Revised Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) in the Prevention of Malaria among Pregnant Women in Northern Ghana. *Journal of Tropical Medicine* 2020, 2020, 1–9. https://doi.org/10.1155/ 2020/2325304.
- 11. Gutman, J.; Kalilani, L.; Taylor, S.; Zhou, Z.; Wiegand, R.E.; Thwai, K.L.; Mwandama, D.; Khairallah, C.; Madanitsa, M.; Chaluluka, E.; et al. The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. *Journal of Infectious Diseases* 2015, 211, 1997–2005. https://doi.org/10.1093/infdis/jiu836.
- 12. Anchang-Kimbi, J.K.; Kalaji, L.N.; Mbacham, H.F.; Wepnje, G.B.; Apinjoh, T.O.; Ngole Sumbele, I.U.; Dionne-Odom, J.; Tita, A.T.N.; Achidi, E.A. Coverage and effectiveness of intermittent preventive treatment in pregnancy with sulfadoxine–pyrimethamine (IPTp-SP) on adverse pregnancy outcomes in the Mount Cameroon area, South West Cameroon. *Malaria Journal* 2020, 19. https://doi.org/10.1186/s12936-020-03155-2.
- 13. Mandal, S.; Sarkar, R.R.; Sinha, S. Mathematical models of malaria a review. *Malaria Journal* **2011**, 10. https://doi.org/10.1186/1475-2875-10-202.
- 14. Smith, D.L.; Battle, K.E.; Hay, S.I.; Barker, C.M.; Scott, T.W.; McKenzie, F.E. Ross, Macdonald, and a Theory for the Dynamics and Control of Mosquito-Transmitted Pathogens. *PLoS Pathogens* **2012**, *8*, e1002588–e1002588. https://doi.org/10.1371/journal.ppat.1002588.
- 15. Wallace, D.I.; Southworth, B.S.; Shi, X.; Chipman, J.W.; Githeko, A.K. A comparison of five malaria transmission models: benchmark tests and implications for disease control. *Malaria Journal* **2014**, *13*. https://doi.org/10.1186/1475-2875-13-268.
- 16. Pande, V.; Bahal, M.; Dua, J.; Gupta, A. Ronald Ross: Pioneer of Malaria Research and Nobel Laureate. *Cureus* **2024**, *16*. https://doi.org/10.7759/cureus.65993.



- 17. Ngwa, G.A.; Shu, W.S. A mathematical model for endemic malaria with variable human and mosquito populations. *Mathematical and Computer Modelling* **2000**, *32*, 747–763. https://doi.org/10.1016/S0895-7177 (00)00169-2.
- 18. Chitnis, N.; Cushing, J.M.; Hyman, J.M. Bifurcation Analysis of a Mathematical Model for Malaria Transmission. *SIAM Journal on Applied Mathematics* **2006**, *67*, 24–45. https://doi.org/10.1137/050638941.
- 19. Danquah, B.A.; Chirove, F.; Banasiak, J. Effective and ineffective treatment in a malaria model for humans in an endemic region. *Afrika Matematika* **2019**, *30*, 1181–1204. https://doi.org/10.1007/s13370-019-00713-z.
- Ayalew, A.; Molla, Y.; Woldegbreal, A. Modeling and Stability Analysis of the Dynamics of Malaria Disease Transmission with Some Control Strategies. Abstract and Applied Analysis 2024, 2024. https://doi.org/10.1155/2024/8837744.
- 21. Ghosh, M.; Lashari, A.A.; Li, X.Z. Biological control of malaria: A mathematical model. *Applied Mathematics and Computation* **2025**, 2013, 7923–7939. https://doi.org/10.1016/j.amc.2013.02.053.
- 22. Mwamtobe, P.M.; Abelman, S.; Tchuenche, M.J.; Kasambara, A. Optimal (Control of) Intervention Strategies for Malaria Epidemic in Karonga District, Malawi. *Abstract and Applied Analysis* **2014**, 2014, 1–20. https://doi.org/10.1155/2014/594256.
- 23. Birkhoff, G.; Rota, G.C. Ordinary Differential Equations, 4 ed.; John Wiley & Sons: New York, 1978.
- Driessche, P.v.d.; Watmough, J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. *Mathematical Biosciences* 2002, 180, 29–48. https://doi.org/10.1016/s0025-5564(02)00108-6.
- Adom-Konadu, A.; Lanor Sackitey, A.; Anokye, M. Local Stability Analysis Of Epidemic Models Using A Corollary Of Gershgorin's Circle Theorem. *Applied Mathematics E-Notes* 2023, 23, 159–174.
- 26. Allen, L.J. *An Introduction to Mathematical Biology*; Pearson Prentice Hall: Upper Saddle River, NJ, 2007; pp. 162–163.
- 27. LaSalle, J. Some Extensions of Liapunov's Second Method. *IRE Transactions on Circuit Theory* **1960**, *7*, 520–527. https://doi.org/10.1109/tct.1960.1086720.
- 28. UNFPA. Malawi, 2022.
- 29. UNFPA. The State of the World's Midwifery 2014 | United Nations Population Fund, 2022.
- 30. Konlan, M. Modeling the Inflow of Exposed and Infected Migrants on the Dynamics of Malaria. *European Journal of Mathematical Analysis* **2024**, *4*, 7–7. https://doi.org/10.28924/ada/ma.4.7.
- 31. Niger, A.M.; Gumel, A.B. Mathematical analysis of the role of repeated exposure on malaria transmission dynamics. *Differential Equations and Dynamical Systems* **2008**, *16*, 251–287. https://doi.org/10.1007/s12591-008-0015-1.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.